# Phathom Pharmaceuticals

> Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company built around vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB) it licensed from Takeda in 2019 for the U.S., Europe and Canada. Its lead product, VOQUEZNA, won FDA approval in late 2023 - the first major innovation in U.S. GERD treatment in over 30 years - and is sold for non-erosive and erosive GERD plus H. pylori infection via its DUAL PAK and TRIPLE PAK regimens. The company reached $175.1 million in net revenue in 2025 and expects operating profitability in 2026.

- **Founded:** 2019
- **Headquarters:** Florham Park, New Jersey, United States
- **Founders:** Tachi (Tadataka) Yamada (Founder & Chairman (deceased Aug 2021)), Frazier Healthcare Partners (Founding investor / co-launcher), Takeda Pharmaceutical Company (Licensor / founding partner)
- **Team size:** ~430 employees
- **Products:** VOQUEZNA (vonoprazan) tablets, VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK
- **Notable:** Secured FDA approval for VOQUEZNA in late 2023 - the first major GERD treatment innovation in the U.S. in over 30 years., Obtained 10 years of FDA regulatory exclusivity for VOQUEZNA tablets through May 3, 2032., Grew net revenue to $175.1 million in 2025, a 217% year-over-year increase.

## Products & services

- **VOQUEZNA (vonoprazan) tablets** — A first-in-class potassium-competitive acid blocker (P-CAB) approved by the FDA for non-erosive GERD heartburn relief and for the healing and maintenance of erosive GERD in adults.
- **VOQUEZNA TRIPLE PAK** — Co-packaged vonoprazan, amoxicillin and clarithromycin for the treatment of H. pylori infection in adults.
- **VOQUEZNA DUAL PAK** — Co-packaged vonoprazan and amoxicillin as a dual-therapy regimen for H. pylori infection in adults.

## Achievements

- Secured FDA approval for VOQUEZNA in late 2023 - the first major GERD treatment innovation in the U.S. in over 30 years.
- Obtained 10 years of FDA regulatory exclusivity for VOQUEZNA tablets through May 3, 2032.
- Grew net revenue to $175.1 million in 2025, a 217% year-over-year increase.
- Surpassed 1.1 million total VOQUEZNA prescriptions filled by year-end 2025.
- Expanded approval to cover the broader GERD patient population in 2024.

## Latest updates

- **2026-02** — Reported full-year 2025 net revenue of $175.1M (up 217%) and issued 2026 guidance, projecting operating profitability.
- **2026-01** — Completed an underwritten public offering with gross proceeds of approximately $130 million.
- **2025-10** — Q3 2025 net revenue of $49.5M, up 25% quarter over quarter; over 790,000 cumulative prescriptions filled.
- **2025-04** — Steven Basta appointed President and CEO, succeeding Terrie Curran.

## Links

- Website: https://phathompharma.com
- LinkedIn: https://www.linkedin.com/company/phathompharma
- Twitter/X: https://twitter.com/phathompharma

---

Profile page: https://yespress.io/phathom-pharmaceuticals
Published by YesPress — https://yespress.io
Last updated: 2026-06-20